Summit Therapeutics (SMMT) Assets (2020 - 2026)

Summit Therapeutics (SMMT) has 7 years of Assets data on file, last reported at $752.2 million in Q2 2026.

• Quarterly Assets rose 132.13% year-over-year to $752.2 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $752.2 million (up 132.13% YoY) and the FY2025 annual result came in at $751.2 million, up 72.46% from the prior year.
• Assets advanced to $752.2 million in Q2 2026, from $647.9 million in the prior quarter.
• In the past five years, Assets ranged from a high of $752.2 million in Q2 2026 to a low of $95.7 million in Q2 2022.
• A 5-year average of $362.4 million and a median of $292.9 million in 2025 frame the typical range for Assets.
• Annual changes were most pronounced in 2022 — Assets soared 485.82% — and 2023, when it slumped 69.44%.
• Tracing SMMT's Assets over 5 years: stood at $664.2 million in 2022, then tumbled by 69.44% to $202.9 million in 2023, then soared by 114.62% to $435.6 million in 2024, then surged by 72.46% to $751.2 million in 2025, then advanced by 0.13% to $752.2 million in 2026.
• The last three Assets figures came in at $752.2 million (Q2 2026), $647.9 million (Q1 2026), and $751.2 million (Q4 2025), per Business Quant data.